Spots Global Cancer Trial Database for fosaprepitant
Every month we try and update this database with for fosaprepitant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fosaprepitant in Patients Receiving Ifosfamide-based Regimen | NCT01490060 | Sarcoma Chemotherapy-in... Effects of Chem... Adverse Effects... | Fosaprepitant Dexamethasone 5HT3 receptor a... Ifosfamide-base... Doxorubicin Mesna Ifosfamide Vincristine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | NCT05841849 | Breast Cancer Chemotherapy-in... | Aprepitant Palonosetron Fosaprepitant | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer | NCT05564286 | Cervical Cancer Nasopharyngeal ... Chemotherapy-in... Radiation-Induc... Antiemetic | Fosaprepitant tropisetron Dexamethasone | 18 Years - 75 Years | Shantou University Medical College | |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | NCT02780609 | Multiple Myelom... | Selinexor Melphalan Dexamethasone Autologous Hema... Fosaprepitant | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma | NCT01874119 | Chemotherapy-in... | Fosaprepitant | 18 Years - 90 Years | St. Louis University | |
| Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer | NCT05242874 | Chemotherapy-in... | Fosaprepitant ,... Fosaprepitant ,... | 18 Years - 70 Years | Henan Cancer Hospital | |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | NCT05841849 | Breast Cancer Chemotherapy-in... | Aprepitant Palonosetron Fosaprepitant | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy | NCT02407600 | Non-small Cell ... Vomiting Nausea Emesis | FOSAPREPITANT (... Placebo | 18 Years - | State University of New York - Upstate Medical University | |
| Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients | NCT04873284 | Chemotherapy In... Pediatric Cance... | fosaprepitant aprepitant Granisetron plu... | 2 Years - 12 Years | Shanghai Children's Medical Center | |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting | NCT01432015 | Ovarian Cancer Uterine Cancer | fosaprepitant aprepitant Oral Placebo IV placebo | 18 Years - | Gynecologic Oncology Associates | |
| Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer | NCT05564286 | Cervical Cancer Nasopharyngeal ... Chemotherapy-in... Radiation-Induc... Antiemetic | Fosaprepitant tropisetron Dexamethasone | 18 Years - 75 Years | Shantou University Medical College |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
